Financial Analysis: Aktis Oncology (NASDAQ:AKTS) & Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and Aktis Oncology (NASDAQ:AKTS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Profitability

This table compares Protagonist Therapeutics and Aktis Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics 62.04% 42.83% 40.29%
Aktis Oncology -706.81% -26.86% -18.13%

Valuation and Earnings

This table compares Protagonist Therapeutics and Aktis Oncology”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics $46.02 million 176.57 -$130.15 million $4.72 26.38
Aktis Oncology $6.50 million 138.15 -$63.73 million ($1.36) -12.25

Aktis Oncology has lower revenue, but higher earnings than Protagonist Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Protagonist Therapeutics and Aktis Oncology, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics 0 0 16 1 3.06
Aktis Oncology 1 0 9 1 2.91

Protagonist Therapeutics currently has a consensus price target of $166.67, suggesting a potential upside of 33.87%. Aktis Oncology has a consensus price target of $35.62, suggesting a potential upside of 113.91%. Given Aktis Oncology’s higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Protagonist Therapeutics.

Institutional and Insider Ownership

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Aktis Oncology on 11 of the 13 factors compared between the two stocks.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

About Aktis Oncology

(Get Free Report)

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.